Fig. 2.
Fig. 2. Progression-free survival in patients with relapsed B-cell lymphomas. / Fifty-two patients were treated with 131I-tositumomab, etoposide, cyclophosphamide, and ASCT (thin line), and 105 patients were treated with external-beam TBI (1.5 Gy twice a day for 4 days), etoposide (60 mg/kg), cyclophosphamide (100 mg/kg), and ASCT (thick line).

Progression-free survival in patients with relapsed B-cell lymphomas.

Fifty-two patients were treated with 131I-tositumomab, etoposide, cyclophosphamide, and ASCT (thin line), and 105 patients were treated with external-beam TBI (1.5 Gy twice a day for 4 days), etoposide (60 mg/kg), cyclophosphamide (100 mg/kg), and ASCT (thick line).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal